Jones Jesse, Jang Sunyoung, Getch Christopher C, Kepka Alan G, Marymont Maryanne H
Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Neurosurg Focus. 2007;23(6):E7. doi: 10.3171/FOC-07/12/E7.
Radiosurgery has proven useful in the treatment of small arteriovenous malformations (AVMs) of the brain. However, the volume of healthy tissue irradiated around large lesions is rather significant, necessitating reduced radiation doses to avoid complications. As a consequence, this can produce poorer obliteration rates. Several strategies have been developed in the past decade to circumvent dose-volume problems with large AVMs, including repeated treatments as well as dose, and volume fractionation schemes. Although success on par with that achieved in lesions smaller than 3 ml remains elusive, improvements over the obliteration rate, the complication rate or both have been reported after conventional single-dose stereotactic radiosurgery (SRS). Radiosurgery with a marginal dose or peripheral dose < 15 Gy rarely obliterates AVMs, yet most lesions diminish in size posttreatment. Higher doses may then be reapplied to any residual nidi after an appropriate follow-up period. Volume fractionation divides AVMs into smaller segments to be treated on separate occasions. Doses > 15 Gy irradiate target volumes of only 5-15 ml, thereby minimizing the radiation delivered to the surrounding brain tissue. Fewer adverse radiological effects with the use of fractionated radiosurgery over standard radiosurgery have been reported. Advances in AVM localization, dose delivery, and dosimetry have revived interest in hypofractionated SRS. Investigators dispensing >or= 7 Gy per fraction minimum doses have achieved occlusion with an acceptable number of complications in 53-70% of patients. The extended latency period between treatment and occlusion, about 5 years for emerging techniques (such as salvage, staged volume, and hypofractionated radiotherapy), exposes the patient to the risk of hemorrhage during that period. Nevertheless, improvements in dose planning and target delineation will continue to improve the prognosis in patients harboring inoperable AVMs.
放射外科已被证明在治疗脑部小型动静脉畸形(AVM)方面很有用。然而,大型病变周围受照射的健康组织体积相当大,因此需要降低辐射剂量以避免并发症。结果,这可能导致闭塞率较低。在过去十年中,已经开发了几种策略来规避大型AVM的剂量 - 体积问题,包括重复治疗以及剂量和体积分割方案。尽管与小于3毫升的病变所取得的成功相当仍难以实现,但在传统单剂量立体定向放射外科(SRS)后,已报告在闭塞率、并发症率或两者方面有所改善。边缘剂量或周边剂量<15 Gy的放射外科很少能使AVM闭塞,但大多数病变在治疗后会缩小。在适当的随访期后,可对任何残留的病灶再次给予更高剂量。体积分割将AVM分成较小的部分,在不同时间进行治疗。剂量>15 Gy仅照射5 - 15毫升的靶体积,从而使传递到周围脑组织的辐射最小化。与标准放射外科相比,使用分割放射外科报告的不良放射学效应较少。AVM定位、剂量传递和剂量测定方面的进展重新激发了对低分割SRS的兴趣。给予每分次最小剂量≥7 Gy的研究者在53% - 70%的患者中实现了闭塞,且并发症数量可接受。治疗与闭塞之间的延迟期延长,新兴技术(如挽救性、分期体积和低分割放疗)约为5年,在此期间患者面临出血风险。然而,剂量规划和靶区勾画的改进将继续改善患有无法手术的AVM患者的预后。